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Some 600 million people worldwide have high blood 
pressure and nearly 3 million die every year as a direct 
result. Yet seven out of every 10 people with hypertension 
are not being treated adequately, according to WHO and 
the International Society of Hypertension (ISH). 
Combination drug therapy is recommended for patients 
whose blood pressure does not fall to optimal levels with 
single-drug treatment. 
Bilayer tablet is new era for successful development of 
controlled release formulation along with various features 
to provide successful drug delivery system. Bilayer tablet 
is suitable for sequential release of two drugs in 
combination, separate two incompatible substances and 
also for sustained release tablet in which one layer is 
immediate release as loading dose and second layer is 
maintenance dose. The immediate release layer of bilayer 
tablet has worked as the loading dose and the sustained 
release layer has maintained therapeutic plasma drug 
concentration for prolonged time. 
It is envisaged that the proposed work is designed as the 
Bilayer tablet of hydrochlorothiazide and candesartan. One 
layer of the bilayer tablet contains the hydrochlorothiazide 
as instant release, and the remaining second layer contains 
the canedesartan as control Layer. Hydrochlorothiazide is 
a thiazide diuretic that helps prevent your body from 
absorbing too much salt, which can cause fluid retention. 
Candesartan is an angiotensin II receptor antagonists. 
Candesartan keeps blood vessels from narrowing, which 
lowers blood pressure and improves blood flow.The 
combination of Hydrochlorothiazide and Candesartan is 
used to treat high blood pressure (hypertension). 
 
MATERIAL AND METHODS 
Materials 
Candesrtan and Hydrochlorothizide (Micro Lab. Hosur); 
HPMC K4 and K15 (Lobachem Pvt. Ltd., Mumbai); 
Sodium starch glycolate (Bioplus Life Science Banglore); 
Cross carmellose sodium, Microcrystaline cellulose and 
Lactose anhydrase (Merck Pvt, Ltd, Mumbai); Magnasium 
stearate, PVP K30 and Talc (S.D.Fine Chemical Ltd, 
Mumbai)   
Methods 
Preformulation 
Physiochemical Properties of candesartan and 
hydrochlorothiazide 
A) Organoleptic evaluation 
It refers to the evaluation by sensory characters-taste, 
appearance, odor, feel of the drug, etc. 
B) Solubility (at room temp: )  
We will check the solubility of both of drugs in water, hot 
water, 0.1N HCL, 0.1 NaOH,  acetone, ethanol, 
chloroform, methanol at room temperature. 
C) Identification Test  
FTIR Spectroscopy  
Infra- red spectrum is an important record which gives 
sufficient information about the structure of a compound.  
This technique provides a spectrum containing a large 
number of absorption band from which a wealth of 
information can be derived about the structure of an 
organic compound. 
D) Loss on drying: Loss on drying directly measuring by 
IR moisture balance. Firstly calibrate the instrument by 
knob then take 5.000 gm sample (powder) and set the temp 
at 100°C to 105°C for 5 minutes and constant reading set 
the knob and check % moisture. 
E) Determination of pH (1 w/v solution in water): 
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1gm of the Powder was taken and dissolved in 100ml of 
distilled water with sonication and filtered, pH of the 
filtrate was checked with standard glass electrode. 
F)  Melting point:
 
 
 It is one of the parameters to judge the purity of 
drugs.  In case of pure chemicals, melting points are very 
sharp and constant.  Since the drugs contain the mixed 
chemicals, they are described with certain range of melting 
point. A small quantity of powder was placed into a fusion 
tube.  That tube is placed in the melting point determining 
apparatus containing castor oil.  The temperature of the 
castor oil was gradual increased automatically and read the 
temperature at which powder started to melt and the 
temperature when all the powder gets melted. 
 G) Bulk properties 
 A known quantity of powder was poured into the 
measuring cylinder carefully level the powder without 
compacting, if necessary and read the unsettled apparent 
volume, Vo, to the nearest graduated unit. Calculate the 
bulk density, in gm per ml gm/cc, by the formula  
Bulk density = Bulk Mass/ Bulk Volume 
 H) Compressibility index (Carr’s index): 
Compressibility index (C.I.) is an important measure that 
can be obtained from the bulk and tapped densities. Carr’s 
index a material having values of less than 20% to 30% is 
defined as the free flowing material. Shown in Table 1. 
It can be calculated as per given formula: 
 
Table 1: Carr’s index range 
S. no. % Comp. Index Properties 
1 5-12 Excellent 
2 12-16 Good 
3 18-21 Fair – passable 
4 23-25 Poor 
5 33-38 Very Poor 
6 >40 Extremely poor 
 
I)  Hausner ratio: 
It indicates the flow properties of the powder and is 
measured by the ratio of tapped density to bulk density. 
Shown in Table 2. 
                  Hausner ratio = Tapped density / Bulk Density
  
Table 2: Hausner ratio and flow property 
characteristics 
S. no. Hausner ratio Property 
1. 0.0 - 1.2 Free flowing 
2. 1.2 - 1.6 Cohesive powder 
Standard value of Hausner ratio is 1.25. 
J) Angle of repose: 
The angle of repose is a relatively simple technique for 
estimating the flowability of a powder through a funnel 
and fall freely onto a surface. The height and diameter of 
the resulting cone is measured and using the following 
equation, the angle of repose can be calculated.  
Tan θ = h/r 
Where    h, r is the relatively height and radius of the 
powder cone. 
For most pharmaceutical powders, the angle of repose 
values range form 25 to 45, with lower values indicating 
better flow characteristics. Values of angle of repose ≤ 30 
usually indicate a free flowing material and angle ≥40 
suggest a poorly flowing material. 
k)  MOISTURE CONTENT DETERMINATION 
Principle: The titrimetric determination of water is based 
upon the quantitative reaction of water with an anhydrous 
solution of sulphur dioxide and iodine in the presence of a 
buffer that reacts with hydrogen ions. In the original 
titrimetric solution, known as Karl Fisher Reagents, the 
sulfur dioxide and iodine was dissolved in pyridine and 
methanol. The test specimen may be titrated with the 
reagent directly, or the analysis may be carried out by a 
residual titration procedure. The stoichiometry of the 
reaction is not exact, and the reproducibility of a 
determination depends upon such factors as the relative 
concentration of the reagent ingredients, the nature of the 
inert solvent used to dissolve the test specimen, and the 
technique used in the particular determination. Therefore, 
an empirically standardized technique is used in order to 
achieve the desired accuracy. Precision in the method is 
governed largely by the extent to which atmospheric 
moisture is excluded from the system. The titration of 
water is usually carried out with the use of anhydrous 
methanol as the solvent for the test specimen; however 
other suitable solvents may be used for special or unusual 
test specimens.   (Note: Now-a-days pyridine free KF 
reagents are coming in which pyridine is replaced by the 
imidazole, because pyridine has carcinogenic effects). 
L) DETERMINATION OF λ max. OF CANDESARTAN 
Accurately weighed 10 mg of drug was dissolved in 10 ml 
of 6.8 PH buffer solution in 10 ml of volumetric flask.the 
resulted solution 1000µg/ml and from this solution 1 ml 
pippet out and transfer into 10 ml volumetric flask and 
volume make up with 6.8 PH buffer solution prepare 
suitable dilution to make it to a concentration range of 5-
25 μg/ml. The spectrum of this solution was run in 200-
400 nm range in U.V spectrophotometer (Labindia-
3000+).The Candesartan shows the absorbance maxima at 
257 nm in 6.8 PH buffer solution. 
M)  DETERMINATION OF λ max. OF 
HYDROCHLOROTHIAZIDE 
Accurately weighed 10 mg of drug was dissolved in 10 ml 
of 6.8 PH buffer solution (methanol used as cosolvent) in 
10 ml of volumetric flask. The resulted solution 
1000µg/ml and from this solution 1 ml pippet out and 
transfer into 10 ml volumetric flask and volume make up 
with 6.8 PH buffer solution prepare suitable dilution to 
make it to a concentration range of 5-25 μg/ml. The 
spectrum of this solution was run in 200-400 nm range in 
U.V spectrophotometer (Labindia-3000+). The 
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Hydrochlorothiazide shows the absorbance maxima at 272 
nm in 6.8 PH buffer solutions. 
PHASE-I PREPRATION OF INSTANT LAYER OF 
HYDROCHLOROTHIAZIDE 
Fast dissolving tablets of Hydrochlorothiazide were 
prepared by direct compression method after incorporating 
different superdisintegrants such as, crosscarmellose 
sodium (Ac-Di-Sol), crospovidone and sodium starch 
glycolate in different concentrations. The above 
ingredients was weighed and mixed in geometric 
progression in a dry and clean mortar. Then the ingredients 
were passed through mesh #60.  
Magnesium  stearate  as lubricant and  talc as glidant were  
added  in  a  final  step and mixed,  this  blend was  
subjected  to  analysis  of  pre-compression parameters 
which included Angle of repose, Bulk density, Tap 
density, Carr’s index and Hausner’s ratio.  
The Blend was compressed on 8 mm (diameter) fat 
punches on a ‘Rimek mini press 16 station rotary 
compression machine. Eight formulations of 
Hydrochlorothiazide granules were prepared and  each  
formulation  contained  one  of  the  three  disintegrant  in  
different concentration. Each tablets weighing 100 mg, 
were obtained. Composition of tablets is mentioned in 
Table 3. 
Table 3: Composition of Hydrochlorothiazide Fast Dissolving Tablets 
Ingredients(mg) Formulation code 
TM1 TM2 TM3 TM4 TM5 TM6 TM7 TM8 TM9 
Hydrochlorothiazide    25    25   25   25   25   25   25   25   25 
Sodium 
Starch glycolate 
   4    6    8    _   _ 
 
_ _ _ _ 
Croscarmellose odium   _   _    _     4    6    8   _   _   _ 
Crospovidone   _   _   _   _    _     _    4    6    8 
Microcrystalline 
cellulose 
  65   65   65   65   65   65   65   65   65 
Magnesium stearate   06   04   02   06   04   02   06   04`   02 
Total weight 100 100 100 100 100 100 100 100 100 
 
EVALUATION OF POSTCOMPRESSION 
PARAMETER 
1. Shape and colour of tablets: 
Uncoated tablets were examined under a lens for the shape 
of the tablet and colour was observed by keeping the 
tablets in light. 
 Thickness test 
Three tablets were picked from each formulation randomly 
and thickness was measured individually. It is expressed in 
mm and standard deviation was also calculated. The tablet 
thickness was measured using dial-caliper (Mitutoyo, 
Japan). 
 Weight variation test 
Twenty tablets were selected randomly from each 
formulation and average weight was  determined.  The 
tablets were weighed individually and compared with 
average weight. The U.S Pharmacopoeia allows a little 
variation in the weight of a tablet. The following 
percentage deviation in weight variation is allowed (Table 
No.6.7).   
 
Table 4: Percentage deviation in weight variation 
S. NO. Average Weight of A Tablet Percentage Deviation 
1. 130 mg or less 10 
2. More than 130 mg and less than 324 mg 7.5 
3. 324 mg or more  5 
 
In all the formulations the tablets weight is more than 130 
mg and less than 324 mg, hence 7.5% maximum difference 
allowed. 
 Hardness test 
The hardness of tablet was measured by Pfizer hardness 
tester and results were expressed in Kg/cm2. 
 Friability test 
For this, 20 tablets were taken from each formulation and 
the friability was determined using Roche friabilator. The 
equipment was run for 4min at 25 revolutions per minute. 
The tablets were taken out,  dedusted  and reweighted and 
% friability was calculated. The friability was determined 
as the mass loss in percent according to Equation:- 
 
The test complies if tablets not lose more than 1% of their 
weight 
 Uniformity of drug content:  
The test is mandatory for tablets with 10 mg or less weight 
of active ingredient. Ten randomly selected tablets from 
each formulation (F1 to F9) were finely powdered and 
Drug equivalent  to  10  mg of drug dissolved in 10 ml  0.1  
N  HCl  (simulated gastric ﬂuid  of pH 1.2 without 
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enzymes) sonicate it for 20  minutes,  till  the  entire  drug 
leached  out  from  complex,  then  the  solution was  
filtered  through  whatman  filter  paper No. 41. From this 
Solution take 1ml and Diluted up to 100 ml with 0.1 N 
HCl and the drug content was determined 
spectrophotometrically at 272.0 nm. 
PREPRATION OF CANDESARTAN MATRIX 
TABLET 
Direct compression was followed to manufacture the gas 
generating floating tablets of simvastatin. All the polymers 
selected, drug and excipients were passed through sieve 
no. 40 before using into formulation. Polymers selected for 
tablets are HPMC K15, HPMC K4, PVP-K30. Excipients 
like Lactose anhydrous,Talc, Magnesium Stearate were 
selected for the study.  
Steps involved in the manufacture of tablets 
  First the drug, polymer and other excipients 
selected were passed through 40- mesh sieve. Required 
quantity of drug, polymer and excipients were weighed 
properly and transferred into polyethylene bag and the 
blend was mixed for at least 15 min. 
 The blend obtained was then lubricated by adding 1% 
magnesium stearate and again mixed for another 5min.
 
Table 5:  Various formulation of Candesartan Matrix tablet 
Excipients F1 F2 F3 F4 F5    F6    F7    F8   F9 
Candesartan 32 32 32 32 32 32 32 32 32 
HPMC K 4 130 120 110 - - - 65 60 55 
HPMC K 15 - - - 130 120 110 65 60 55 
Lactose anhydrous 18 28 38 18 28 38 18 28 38 
PVP-k30 16 16 16 16 16 16 16 16 16 
Talc 2 2 2 2 2 2 2 2 2 
Magnesium stearate 2 2 2 2 2 2 2 2 2 
Total 200 200 200 200 200 200 200 200 200 
 
EVALUATION OF MATRIX TABLET 
All the tablets were evaluated for following different 
parameters which includes; 
1. General Appearance 
Five tablets from different batches were randomly selected 
and organoleptic properties such as color, odor, taste, 
shape, were evaluated. Appearance was judged visually. 
Very good (+++), good (++), fair (+) poor (-), very poor (- 
-). 
2. Thickness and diameter 
Thickness and diameter of tablets were determined using 
Vernier caliper. Five tablets from each batch were used, 
and an average value was calculated. 
3. Hardness 
For each formulation, the hardness of five tablets was 
determined using the Monsanto hardness tester (Cadmach). 
4. Friability 
The friability of a sample of 10 tablets was measured using 
a Friability tester (Electro Lab). Ten tablets were weighed, 
rotated at 25 rpm for 4 minutes. Tablets were reweighed 
after  removal of fines (dedusted) and the percentage of 
weight loss was calculated. 
5. Uniformity of weight 
Twenty tablets were randomly selected from each batch 
individually weighed, the average weight and standard 
deviation of 20 tablets was calculated. 
6. Drug content 
Twenty tablets were taken and amount of drug present in 
each tablet was determined. The tablets were crushed in a 
mortar and the powder equivalent to 100 mg of drug was 
transferred to 100ml standard flask. The powder was 
dissolved in 50 ml of pH 6.8 Phosphate Buffer and made 
up to volume with buffer. The sample was mixed 
thoroughly and filtered through a 0.45μ membrane filter. 
The filtered solution was diluted suitably and analyzed for 
drug content by UV spectrophotometer at a λmax of 257.0 
nm using of pH 6.8 Phosphate Buffer as blank. 
 Dissolution rate studies 
 In vitro drug release of the sample was carried out using 
USP- type II dissolution apparatus (Paddle type). The 
dissolution medium, 900 ml pH 6.8 Phosphate Buffer 
(Tween 20, 0.1%) was placed into the dissolution flask 
maintaining the temperature of 37±0.50c and rpm of 50. 
One Candesartan Control layer tablet was placed in each 
basket of dissolution apparatus. The apparatus was allowed 
to run for 12 hours. Sample measuring 4 ml were 
withdrawn after 30 min., 1.0 hr, 1.30 hr, 2.0 hr, 3hr., 4.0 
hr, 6.0 hr, 8.0hr 10.0 hr, 12 hour using 4 ml pipette. The 
fresh dissolution medium was replaced every time with the 
same quantity of the sample.  
FORMULATION OF BILAYER TABLETS 
Optmized bach of Instant Layer (TM4) and Optmized bach 
of Sustain layer(F7) used to formulate Bilayer tablet of 
Hydrochlorothiazide and Candesartan. Procedure of 
formulation same as method as previous. 
All the tablets were evaluated for following different 
parameters which includes; 
1. General Appearance 
Five tablets from different batches were randomly selected 
and organoleptic properties such as color, odor, taste, 
shape, were evaluated. Appearance was judged visually. 
Very good (+++), good (++), fair (+) poor (-), very poor (- 
-). 
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2. Thickness and diameter 
Thickness and diameter of tablets were determined using 
Vernier caliper. Five tablets from each batch were used, 
and an average value was calculated. 
3. Hardness 
For each formulation, the hardness of five tablets was 
determined using the Monsanto hardness tester (Cadmach). 
4. Friability 
The friability of a sample of 10 tablets was measured using 
a Friability tester (Electro Lab). Ten tablets were weighed, 
rotated at 25 rpm for 4 minutes. Tablets were reweighed 
after removal of fines (dedusted) and the percentage of 
weight loss was calculated. 
5. Uniformity of weight 
Twenty tablets were randomly selected from each batch 
individually weighed, the average weight and standard 
deviation of 20 tablets was calculated. 
6. Drug content 
Twenty tablets were taken and amount of drug present in 
each tablet was determined. The tablets were crushed in a 
mortar and the powder equivalent to 32 mg of Candesartan 
was transferred to 100ml standard flask. The powder was 
dissolved in 50 ml of methanol and made up to volume 
with methanol. The sample was mixed thoroughly and 
filtered through a 0.45μ membrane filter. The filtered 
solution was further diluted 1 ml to 10ml suitably (32 ppm 
of candesartan and 25 ppm of Hydrochlorothiazide) and 
Determine the Conc. of both drugs using Simultaneous 
estimation method  
7. Dissolution rate studies 
In vitro drug release was performed according to the USP 
dissolution apparatus II at 50 rpm and 37±0.5ºC 
temperature over a 12 hrs period for Candesartan SR and 2 
hr for Hydrochlorothiazide IR, using an automated paddle 
dissolution system (Labindia). A minimum of 6 tablets per 
batch were tested. 
The media used was 0.1N HCl at a pH 1.2 and a volume of 
900 ml for the first 2 hours after and then pH of 6.8 and 
maintained at 37+ 0.5◦C upto 12 Hours. Test sample (4ml) 
was withdrawn at particular time interval and replaced 
with fresh dissolution media maintained at the same 
temperature and the concentration of dissolved drug was 
determined using U.V. (Ultraviolet Labindia 3000+) 
spectrophotometer at λmax 257 nm for Candesartan and 
272.0 nm for Hydrochlorothiazide.  
RESULTS AND OBSERVATION 
PREFORMULATION  
PHYSICO-CHEMICAL PROPERTIES OF 
CANDESARTAN AND HYDRO 
-CHLOROTHIAZIDE 
A). Organoleptic evaluation:             
Table 6: Organoleptic property of Candesartan 
Color white 
Odor characteristic 
                                                                                                                             
Table 7: Organoleptic property of Hydrochlorothiazide 
Color  White 
Odor  Characteristic 
 
B) Solubility: 
Solubility study of Candesartan and hydrochlorothiazide 
has been done in various solvent such as water, Phosphate 
buffer pH 6.8, Phosphate buffer pH 7.4 and 0.1 N HCl 
solution. We were found that a solubility of candesartan 
and hydrochlorothiazide were slightly soluble in a 0.1 N 
HCl solution. 
 
Table 8: Solubility in various solvent 
S. No. Solvent Candesartan Hydrochlorothiazide 
1 Water In soluble In soluble 
2 Ethanol Freely soluble Soluble 
3 Methanol Freely soluble Soluble 
4 Acetone Freely soluble Soluble 
5 0.1N HCl Slightly soluble Slightly soluble 
6 6.8 pH buffer Soluble Soluble 
7 7.4 pH buffer Soluble Soluble 
                                     
C) Identification test by FTIR: 
Identification of Candesartan and Hydrochlorothiazide by 
FTIR Spectroscopy with respect to marker compound 
Candesartan and Hydrochlorothiazide was obtained as 
White or almost white crystalline powder. It was identified 
from the result of IR spectrum as per specification. 
Sample of pure Candesartan and Hydrochlorothiazide 
The IR spectrum of sample drug shows the peak values 
which are characteristics of the drug and the graph was 
shown in figure no. 7.1 and 7.2. 
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Figure 1: FT-IR Spectrum of Pure Drug (Candesartan) zide) 
 
Figure 2: FT-IR Spectrum of Pure Drug (Hydrochlorothia 
 
 
Figure 3: FT-IR Spectrum of Candesartan and excipients 
 
 
Figure 4: FT-IR Spectrum of Hydrochlorothiazide and Excipients 
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E) Loss on Drying (LOD): 
Procedure: Loss on drying directly measuring by IR 
moisture balance. Firstly calibrate the instrument by knob 
then take 1.000 gm sample (powder) and set the temp at 
100°C to 105°C for 5 minutes and constant reading set the 
knob and check % moisture. 
Result: The percentage of loss on drying of Candesartan 
and hydrochlorothiazide 0.020 %w/w and 0.0255 %w/w. 
F) Determination of pH (1 w/v solution in water): 
The pH determination of Candesartan and 
Hydrochlorothiazide was done by Digital pH meter and 
found to be 6.4 and.4.43. 
G) Melting Point: 
Procedure: A small quantity of powder was placed into a 
fusion tube.  That tube is placed in the melting point 
determining apparatus containing castor oil.  The 
temperature of the castor oil was gradually increased 
automatically and read the temperature at which powder 
started to melt and the temperature noted when all the 
powder gets melted. 
Result: Melting point of Candesartan and 
Hydrochlorothiazide determine by Melting point apparatus 
at 157-160
0
C and 265-280°C. 
H) Flow Property of Candesartan and 
Hydrochlorothiazide Powder: 
 Bulk density: 
A known quantity of powder was poured into the measuring 
cylinder carefully level the powder with out compacting, if 
necessary and read the unsettled apparent volume, Vo, to the 
nearest graduated unit. Calculate the bulk density, in gm/ml 
gm/cc, by the formula.  
Bulk density = Bulk Mass/ Bulk Volume
 
Table 9: Bulk Density of Candesartan and Hydrochlorothiazide 
S. No. Density Candesartan Hydrochlorothiazide 
1 Untapped density 0.22 g/cc 0.4 g/cc 
2 Tapped density(after 50 tapping) 0.40 g/cc 0.71 g/cc 
 
 Compressibility Index (%) 
             OR 
 
Result: The compressibility index of Candesartan and 
hydrochlorothiazide respectively is 45% and 44.2%. 
 Hausner ration: 
Hausner Ratio = Tapped density / Bulk Density 
Result: The Hausner ration of candisaratn and 
hydrochlorothiazide respectively is 1.818 and 1.77. 
 Angle of Repose 
Procedure: The angle of repose is a relatively simple 
technique for estimating the flowability of a powder 
through a funnel and fall freely onto a surface. The height 
and diameter of the resulting cone is measured and using 
the following equation, the angle of repose can be 
calculated. Weigh 10 gm of drug (Candesartan and 
Hydrochlorothiazide) powder accurately, and pass through 
the fennel height up to2.5 cm from surface and measure 
the height and diameter by scale. 
Tan θ = h/r 
Where    h, r is the relatively height and radius of the 
powder cone. 
Result: The Angle of repose of Candesartan and 
hydrochlorothiazide 38.0& 37.0 degree respectively. 
Result: Partical size pass through 40# is 100 (%w/w). 
I) Moisture by Karl-Fischer Apparatus (KF) 
Result: The Moisture content of Candesartan and 
hydrochlorothiazide is 0.1095 and 0.073% respectively. 
7.1.2. DETERMINATION OF λMAX BY UV-VISIBLE 
SPECTROSCOPY 
Standard solution (10g/ml) of pure Candesartan and 
Hydrochlorothiazide was prepared. The pure drug 
solutions were scanned on UV spectrophotometer, which 
showed maximum absorbance at 257.0nm and 272.0nm for 
Candesartan and hydrochlorothiazide respectively.  
 Determination of λmax of Candesartan 
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Figure 6: 3D Spectrum of Determination of λmax of 
Candesartan at 257.0nm 
 Determination of λmax of Hydrochlorothiazide 
 
 
Figure: 7 Determination of λmax of 
Hydrochlorothiazide at 272.0nm 
 
 
Figure 8: 3D Spectrum of Determination of λmax of 
Hydrochlorothiazide at 272.0nm 
 Prepration of Calibration Curve of Candesartan 
and Hydrochlorothiazide 
Prepration of Calibration Curve of Candesartan 
Accurately weighed 10 mg of pure Candesartan was 
dissolved in 2.0 ml of methanol and volume make upto 10 
ml with 6.8 pH buffer solution in 10 ml of volumetric flask 
and prepare suitable dilution to make it to a concentration 
of 1000μg/ml make adequate of sample with concentration 
range of 5-25 μg/ml with with 6.8 pH buffer solution. The 
spectrum of this solution was run in 200-400 nm range in 
U.V spectrophotometer. 
 
Figure 9: Standard Calibration Curve of Candesartan 
Regression Equation  
Y=  mx +c,                         
Y= AUC 
m= slope =0.014 
X= Conc. in g/ml                   
 c= Intercept =0.005    
 r
2
=0.999                     
 Prepration of Calibration Curve of 
Hydrochlorothiazide 
Accurately weighed 10 mg of pure Hydrochlorothiazide 
was dissolved in 2.0 ml of methanol and volume make 
upto 10 ml with 6.8 pH buffer solution in 10 ml of 
volumetric flask and prepare suitable dilution to make it to 
a concentration of 1000μg/ml make adequate of sample 
with concentration range of 5-25 μg/ml with with 6.8 pH 
buffer solution. The spectrum of this solution was run in 
200-400 nm range in U.V spectrophotometer.  
 
Figure 10: Standard Calibration Curve of 
Hydrochlorothiazide 
Regression Equation  
Y=  mx +c,                         
Y= AUC 
m= slope =0.032 
X= Conc. in g/ml                   
 c= Intercept =0.027    
 r2=0.995 
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 Optical parameters of Candesartan and Hydrochlorothiazide
Table 10: Result of Optical Parameter of Candesarta and Hydrochlorothiazide 
S. No.   Parameters Observation Candesartan Observation Hydrochlorothiazide 
1 λ max 257.0 nm 272.0 
2 Beer’s law limit (µg/mL) 5-25µg/ml 5-25µg/ml 
3 Regression equation               Y=0.014x-0.005       Y=0.035x+0.010 
4 Correlation Coefficient ( r2 ) 0.999 0.999 
                                       
7.1.3. COMPATIBILITY STUDIES OF DRUG AND 
EXCIPIENTS 
In the compatibility testing program, blends of drug and 
excipients are prepared by triturating the drug with 
Individual excipients. 
Procedure: Take 50 mg accurately weigh of drug dry 
powder and 50 mg of excipients and mix the blend of drug 
and excipients and binary/tertiary blends of extract and 
excipients were prepared and transferred to inert glass 
vials. The mouths of the vials were covered with rubber 
closures followed by the aluminum seal caps. 
Binary/tertiary blends of extract and excipients,  drug neat 
and excipients were stored at 4˚C (refrigerator) as control; 
and at 40˚C/75%RH for accelerated stability studies for 4 
weeks. The visual observations (color, flow, & sticking) 
were recorded for initial and at the end of the first, second, 
third and fourth week. 
7.2. PHASE I- PREPRATION OF INSTANT LAYER 
OF HYDROCHLOROTHIAZIDE 
7.2.1. Evaluation of Pre-compression Parameters:  
Blend ready for compression containing drug and various 
excipients was subjected for pre-compression parameters 
to study the flow properties of granules, to achieve 
uniformity of tablet weight. 
A) Angle of repose (θ): 
 The data obtained for angle of repose for all the 
formulations were tabulated in Table No.7.8. The values 
were found to be in the range of 34o’ to41o. All the 
formulations prepared showed the angle of repose less than 
41°, which reveals passable flow property. 
B) Loose Bulk Density and Tapped Bulk Density:  
Loose bulk density (LBD) and tapped bulk density (TBD) 
for the blend is shown in Table No.7.8 The loose bulk 
density and tapped bulk density for all the formulation 
blend varied from 0.33 gm/cm3 to 0.34  gm/cm3 and 0.50 
gm/cm3 to 0.53 gm/cm3 respectively. 
C) Carr’s compressibility index and Hausner’s ratio:  
  The results of Carr’s consolidation index or 
compressibility index (%) for the entire formulation blend 
ranged from 28.30 to 40.38. The directly compressible 
granulations had shown excellent compressibility index 
values which results in Poor flow properties.  
The results of Hausner’s ratio for all the formulation blend 
is less than 0.570, which shows good flow property. 















TM1 0.33 0.50 34.00 1.515 37o 
TM2 0.32 0.51 37.25 1.594 38o 
TM3 0.31 0.52 40.38 1.677 34o 
TM4 0.33 0.53 37.74 1.606 40o 
TM5 0.30 0.50 40.00 1.667 38o 
TM6 0.34 0.51 33.33 1.500 41o 
TM7 0.32 0.52 38.46 1.625 39o 
TM8 0.38 0.53 28.30 1.395 37o 
TM9 0.35 0.50 30.00 1.429 37o 
 
7.2.2. Evaluation of Post-compression parameters 
A) Shape and colour of tablets:   
Formulations prepared were randomly picked from each 
batch examined under lens for shape and in presence of 
light for colour. Tablets showed flat, circular shape in 
pinkish colour due to add of Colouring agent. 
B) Thickness test                  
Thickness of the tablets was measured by dial caliper by 
picking randomly from all the batches. The results of 
thickness for tablets were shown in Table No. The mean 
thickness was (n=3) almost uniform in all the formulations 
and values ranged from 1.40 ± 0.10 mm. The standard 
deviation values indicated that all the formulations were 
within the range. 
 C) Weight variation test 
The weight variation test is done to ensure the tablet 
contains the proper amount of drug. All the tablets passed 
weight variation test as the average percentage weight 
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variation was within the pharmacopoeial limits of ±10% 
(Table7.9). 
D) Hardness test 
The hardness of all the tablets prepared was maintained 
within the 2.00 kg/cm2 to 4.00 kg/cm2. All the tablets 
maintained hardness in the range 2.51 ± 0.71 kg/cm2 to 
3.59 ± 0.51 kg/cm2for formulations were almost uniform. 
E) Friability test 
The study results tabulated in Table no.7.9 was found to be 
well within the approved range (<1%) in all designed 
formulations. The formulations TM-1 and TM-8 showed 
slightly higher than the other. This might be due to excess 
fines or due to improper granulation, but the values were 
found to be within the limit. Thus tablets possess good 
mechanical strength. 
F) Uniformity of drug content:  
The content uniformity was performed for all the nine 
formulations and results are tabulated in Table No.7.9 
Three trials from each batch were analyzed 
spectrophotometrically. The average value and standard 
deviations of all the formulations were calculated. The 
drug content in  different  formulation  was  highly 
uniform and in the range of 98.51±0.75-99.53±0.42 %.The 
results were within the acceptable range and that indicated 
uniformity of mixing. The cumulative percentage drug 
released by each tablet in the in vitro release studies was 
based on the average drug content present in the tablet.   
G) In-vitro disintegration time: 
It was observed that the disintegration time of tablets 
decreased with increase in the concentration of the 
superdisintegrants. Based on the disintegration results 
(Table 7.10), the formulation containing crosspovidone 
(7.5%) showed the fastest disintegration.     
Among the different formulations, TM4 was chosen as 
optimized batch containing croscarmilose sodium (5%) as 
superdisintegrant, as it has produced the ODT having least 
disintegration time of 12.0 ± 0.21 sec. 




















TM1 3.13 ± 0.21 0.8217± 0.01 Passes 1.42 ±0.03 99.41±0.42 
TM2 3.70 ± 0.30 0.7262 ±0.05 Passes 1.45 ±0.05 99.77±0.51 
TM3 3.51 ± 0.50 0.5314 ±0.03 Passes 1.41 ±0.03 98.53±0.71 
TM4 3.73 ± 0.29 0.6425 ±0.11 Passes 1.40±0.06 99.41±0.49 
TM5 3.81 ± 0.51 0.6346 ±0.05 Passes 1.44 ±0.03 99.33±0.66 
TM6 3.50 ± 0.40 0.7114 ±0.16 Passes 1.46 ±0.05 98.51±0.75 
TM7 3.66 ± 0.29 0.5612 ±0.07 Passes 1.40 ±0.04 99.57±0.42 
TM8 2.77 ± 0.71 0.8554 ±0.11 Passes 1.43 ±0.05 98.33±0.62 
TM9 3.12± 0.42 0.7377 ±0.15 Passes 1.42 ±0.04 99.65±0.48 
 
Table 13: Post-compressional Parameters of All Formulations-II 











7.3. PHASE II- PREPRATION OF CANDESARTAN MATRIX TABLET                  











F1 36 0.38 0.52 26.92 1.37 
F2 33 0.37 0.50 26.00 1.35 
F3 37 0.35 0.51 31.37 1.46 
F4 38 0.39 0.53 26.42 1.36 
F5 35 0.38 0.52 26.92 1.37 
F6 34 0.39 0.53 26.42 1.36 
F7 34 0.40 0.52 23.08 1.30 
F8 38 0.38 0.51 25.49 1.34 
F9 33 0.36 0.51 29.41 1.42 
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F1 3.5 6.5 Passes 0.83 99.12 
F2 3.7 6.4 Passes 0.67 99.25 
F3 3.5 6.3 Passes 0.66 99.23 
F4 3.6 6.4 Passes 0.78 99.21 
F5 3.6 6.5 Passes 066 99.10 
F6 3.4 6.2 Passes 0.89 99.56 
F7 3.5 6.3 Passes 0.74 99.89 
F8 3.4 6.5 Passes 0.99 99.54 
F9 3.6 6.2 passes 0.89 99.26 
 
RELEASE KINETICS OF CANDESARTAN MATRIX TABLET 
 
Figure: 11: Zero order release kinetics data Candesartan Matrix tablet with HPMC K-4 as Binder 
 
Figure 12:  Zero order release kinetics data Candesartan Matrix tablet with HPMC K-15 as Binder 
 
Figure 13:  Zero order release kinetics data Candesartan Matrix tablet with HPMC K-4+ HPMC K-15 as Binder 
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Figure 14:  First order release kinetics data Candesartan Matrix tablet with HPMC K-4 as Binder 
 
Figure no 15: First order release kinetics data Candesartan Matrix tablet with HPMC K-15 as Binder 
 
Figure 16:  First order release kinetics data Candesartan Matrix tablet with HPMC K-4 + HPMC K-15 as Binder 
 
Figure 17:  Higuchi release kinetics data Candesartan Matrix tablet with HPMC K-4 as Binder 
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Figure 18:  Higuchi release kinetics data Candesartan Matrix tablet with HPMC K-15 as Binder 
 
Figure 19: Higuchi release kinetics data Candesartan Matrix tablet with HPMC K4 + K-15 as Binder 
 
Figure 20:  Korsmayer Papas release kinetics data Candesartan Matrix tablet with HPMC K4 as Binder 
 
Figure 21:  Korsmayer Papas release kinetics data Candesartan Matrix tablet with HPMC K-15 as Binder 
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Figure 22:  Korsmayer Papas release kinetics data Candesartan Matrix tablet with HPMC K4 + K-15 as Binder 










2 0.891 0.924 0.978 0.975 
F2 r
2 0.881 0.920 0.981 0.983 
F3 r
2 0.848 0.917 0.982 0.986 
F4 r
2
 0.910 0.965 0.986 0.999 
F5 r
2 0.862 0.959 0.982 0.979 
F6 r
2 0.871 0.980 0.993 0.983 
F7 r
2 0.951 0.673 0.986 0.999 
F8 r
2 0.920 0.974 0.982 0.992 
F9 r
2 0.904 0.966 0.993 0.989 
 
RESULTS OF POST COMPRESSION PROPERTIES OF BILAYER TABLETS 




















TM1 7.12 ± 0.21  0.8217± 0.01 Passes 6.00 ±0.03 99.53±0.42 
TM2 7.70 ± 0.30  0.7262 ±0.05 Passes 6.01 ±0.05 99.41±0.51 
TM3 7.51 ± 0.50  0.5314 ±0.03 Passes 6.01 ±0.03 98.77±0.71 
TM4 7.73 ± 0.29  0.6425 ±0.11 Passes 6.00 ±0.06 99.12±0.49 
TM5 7.81 ± 0.51  0.6346 ±0.05 Passes 6.01 ±0.03 99.33±0.66 
TM6 7.50 ± 0.40  0.7114 ±0.16 Passes 6.01 ±0.05 98.51±0.75 
TM7 7.66 ± 0.29  0.5612 ±0.07 Passes 6.01 ±0.04 99.65±0.42 
TM8 7.77 ± 0.71  0.8554 ±0.11 Passes 4.54 ±0.05 98.80±0.62 
TM9 7.12± 0.42 0.7377 ±0.15 Passes 4.56 ±0.04 99.27±0.48 
 
In vitro drug release study of Bi-layered Tablet of 
Optimized Formulation 
 
Figure 23: release of Hydrochlorothiazide 
In vitro Drug release study of Optimized Formulation No. 
TM-4 of Instant layer and optimized formulation No. F-7of 
Matrix layer. 
 
Figure 24: release of Candesartan 
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In the present study seven formulations with variable conc
entration of polymers (HPMC K-4 and K-15) 
prepared by direct compression method and evaluated for 
physiochemical properties, buoyancy lag time ad invitro 
drug release. The results indicated that optimized 
the gastric fluid, formulation F7 of matrix tablet and TM4 
formulation of instant release on  immersion  in  0.1N  
HCl solution for 2 hour and then at  pH 6.8 phosphate 
buffer at 37±0.50C tablets  
immediately and remain buoyant upto 12hrs without 
disintegration. 
These two factors are essential for the tablet to acquire bul
k density < 1, so that it remains buoyant on The In vitro 
drug release data of the optimized formulation was 
subjected to goodness of fit test by linear regression 
analysis according to zero order, first order kinetic 
equation, Higuchi’s and Korsmeyer’s models in order to 
determine the mechanism of drug release. When the 
regression coefficient values of were compared, it was 
observed that ‘r’ values of first order was maximum i.e 
0.999  hence indicating drug release from formulations 
was found to  follow Korsmeyer’s models. 
CONCLUSION 
Bilayer tablet is improved beneficial technology to 
overcome the shortcoming of the single layered tablet. 
There is various application of the bi-layer tablet it consist 
of monolithic partially coated or multilayered matrices. 
Bilayer tablet is suitable for sequential release of two drugs 
in combination, separate two incompatible substances and 
also for sustained release tablet in which one layer is 
immediate release as initial dose and second layer is 
maintenance dose. The preparation of tablets in the form of 
multi layers is used to provide systems for the 
administration of drugs, which are incompatible and to 
provide controlled release tablet preparations by providing 
surrounding or multiple swelling layers. Bilayer tablet 
quality and GMP-requirements can vary widely. Bilayer 
tablets offer an excellent opportunity for manufacturers to 
separate themselves from their competitors, improve their 
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